Relay Therapeutics Inc. (NASDAQ:RLAY) is one of the 10 best AI driven biotech stocks to invest in. On May 20, JonesResearch ...

One trading session after Relay Therapeutics (NASDAQ: RLAY) announced positive results for an investigational treatment, its shares rocketed higher on Wednesday. That rally, which saw the biotech ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Relay Therapeutics (NASDAQ:RLAY) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ...

Relay Therapeutics RLAY is preparing to release its quarterly earnings on Thursday, 2025-08-07. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and patient ...

According to a Securities and Exchange Commission (SEC) filing dated Feb. 17, 2026, Nextech Invest, Ltd. bought 855,097 additional shares of Relay Therapeutics (NASDAQ:RLAY). The estimated transaction ...

Relay Therapeutics shares are trading lower by 17.8% during Wednesday's session. The company priced its $200 million offering. Next: Access Our New, Shockingly Simple 'Alert System' Relay Therapeutics ...

Relay Therapeutics (NASDAQ:RLAY) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below ...

Nextech Invest increased its stake in Relay Therapeutics by 855,097 shares; the estimated trade value was ~$6.1 million based on average quarterly pricing. Quarter-end position value rose by $19.7 ...